5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) Treatment Decreases Epicardial and Pericardial Adipose Tissue in Patients with Recent Acute Coronary Syndrome

摘要: Background: Epicardial adipose tissue (EAT) has been shown to be associated with coronary atherosclerosis and also as a predictor of future adverse cardiovascular events. VIA-2291, a selective 5-Lipoxygenase inhibitor, has been shown to have anti-inflammatory effects by reduction of leukotriene LTB4. In current study we evaluated the effect of VIA-2291 treatment on EAT and Pericardial Adipose Tissue (PAT) in patients after acute coronary syndrome (ACS) Methods: This is a double blinded: placebo controlled: dose ranging: randomized: multicenter trial (clinicaltrials.gov NCT00358826) of 56 individuals with recent ACS who were recruited and followed for 24 weeks in an imaging substudy. Subjects with chronic liver, kidney and cardiovascular disease were excluded. Subjects on standard of care were randomized to four arms: 25 mg, 50 mg, and 100 mg of VIA-2291 and placebo. EAT and PAT were …